- Home
- CORT vs FSK Comparison
CORT vs FSK Comparison
Compare CORT & FSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CORT
- FSK
- Stock Information
- Founded
- CORT 1998
- FSK 2007
- Country
- CORT United States
- FSK United States
- Employees
- CORT N/A
- FSK N/A
- Industry
- CORT Biotechnology: Pharmaceutical Preparations
- FSK Investment Managers
- Sector
- CORT Health Care
- FSK Finance
- Exchange
- CORT Nasdaq
- FSK Nasdaq
- Market Cap
- CORT 7.1B
- FSK 6.0B
- IPO Year
- CORT N/A
- FSK N/A
- Fundamental
- Price
- CORT $63.54
- FSK $23.70
- Analyst Decision
- CORT Strong Buy
- FSK Hold
- Analyst Count
- CORT 4
- FSK 8
- Target Price
- CORT $97.00
- FSK $20.69
- AVG Volume (30 Days)
- CORT 894.6K
- FSK 1.2M
- Earning Date
- CORT 02-26-2025
- FSK 02-26-2025
- Dividend Yield
- CORT N/A
- FSK 11.82%
- EPS Growth
- CORT 57.97
- FSK N/A
- EPS
- CORT 1.26
- FSK 1.89
- Revenue
- CORT $628,555,000.00
- FSK $1,761,000,000.00
- Revenue This Year
- CORT $46.47
- FSK N/A
- Revenue Next Year
- CORT $21.49
- FSK N/A
- P/E Ratio
- CORT $50.40
- FSK $12.58
- Revenue Growth
- CORT 39.67
- FSK N/A
- 52 Week Low
- CORT $20.84
- FSK $18.31
- 52 Week High
- CORT $75.00
- FSK $24.10
- Technical
- Relative Strength Index (RSI)
- CORT 46.90
- FSK 65.09
- Support Level
- CORT $71.50
- FSK $22.99
- Resistance Level
- CORT $75.00
- FSK $24.10
- Average True Range (ATR)
- CORT 3.33
- FSK 0.33
- MACD
- CORT -0.74
- FSK 0.01
- Stochastic Oscillator
- CORT 3.00
- FSK 76.47
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.
About FSK FS KKR Capital Corp.
FS KKR Capital Corp is a business development company based in the United States. Its portfolio is comprised of investments in senior secured loans and second lien secured loans of private middle market U.S. companies and, to a lesser extent, subordinated loans and certain asset-based financing loans of private U.S. companies. It is focused on providing customized credit solutions to private upper middle-market companies, which it generally defines as companies with annual EBITDA of at least $50 million at the time of investment.